This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Flanigan RC et al. (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655–1659
Mickisch GH et al. (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966–970
Flanigan RC et al. (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171: 1071–1076
Tatsumi T et al. (2003) Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 63: 4481–4489
Jacobsen J et al. (2000) Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163: 343–347
Escudier B et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134
Motzer RJ et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115–124
Hudes G et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271–2281
Escudier B et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103–2111
Rini BI et al. (2008) CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma [Abstract #350]. 2008 ASCO Genitourinary Cancers Symposium: 2008 February 14–16; San Francisco.
Rathmell KA et al. (2008) Neoadjuvant therapy with sorafenib for locally advanced renal cell carcinoma (RCC) [Abstract #370]. 2008 ASCO Genitourinary Cancers Symposium: 2008 February 14–16; San Francisco
Margulis V and Wood CG (2008) Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? Eur Urol 54: 489–492
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Chowdhury, S., Harper, P. & Choueiri, T. The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy. Nat Rev Clin Oncol 5, 698–699 (2008). https://doi.org/10.1038/ncponc1256
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1256
This article is cited by
-
Landmarks in the diagnosis and treatment of renal cell carcinoma
Nature Reviews Urology (2014)
-
Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: biology and pathways
Medical Oncology (2009)